Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca, Oxford Covid-19 Vaccine Up to 90% Effective in Late-Stage Trials -- 5th Update

11/23/2020 | 09:28am EST

By Jenny Strasburg

LONDON -- AstraZeneca PLC and the University of Oxford said their Covid-19 vaccine was as much as 90% effective in preventing infections without serious side effects in large clinical trials, boosting hopes that a third Western-developed shot could be authorized for use before the end of the year.

The partners said Monday that there were no confirmed serious safety events related to the vaccine and that it was well tolerated across different dosing regimens. Its efficacy ranged from 62% to 90% depending on the dosage given, with an average of 70%, they said.

The results bode well for the near-term availability of a third vaccine to battle Covid-19, after a shot created by Moderna Inc. and one made jointly by Pfizer Inc. and Germany's BioNTech SE were found to be more than 90% effective in their own late-stage trials. Pfizer and BioNTech last week said they had asked the U.S. Food and Drug Administration to permit use of their vaccine.

China and Russia have both deployed their own vaccines at home and overseas. Chinese authorities have inoculated nearly one million Chinese people with a vaccine from one state company, though it has yet to provide solid clinical evidence of its efficacy. Russia has said its own homegrown vaccine has an efficacy rate of above 90%.

The AstraZeneca-Oxford vaccine stands out among the leading Western candidates. The partners committed to selling it without profit during the pandemic and promised to distribute it across a much wider geographic footprint, including in large parts of the developing world. The shot is expected to cost $3 to $5 a dose globally during the pandemic.

The shot was created from a more traditional vaccine methodology than the gene-based technology used by Moderna and Pfizer. The Oxford-AstraZeneca shot doesn't need to be stored in subzero temperatures, making its rollout easier, researchers and logistics experts say.

Participants in the trials are 18 years or older with stable underlying medical conditions. There were 131 Covid-19 cases among trial volunteers analyzed in the results. Researchers said that in addition to showing positive results in stopping transmission of the disease, the vaccine was effective in preventing severe symptoms and hospitalizations -- a sought-after benefit to curb Covid-19 deaths and stop hospitals from being overburdened.

AstraZeneca said it would seek emergency-use authorization from the World Health Organization to distribute the vaccine in low-income countries and prepare regulatory submissions to authorities in countries that have early-approval programs.

Pending regulatory authorization, the shot could be available in limited volumes by year-end, with hundreds of millions more doses available each month after that, AstraZeneca executives said Monday. The level of output depends on manufacturers across the world that are working with AstraZeneca to produce the vaccine.

The European Medicines Agency, which authorizes new medicines for sale in the European Union, said in early October that it had begun a rolling review of the Oxford vaccine to speed up a potential approval. A rolling review allows regulators to evaluate preliminary data such as those from lab experiments before final-stage clinical trials are completed.

Officials in the U.K., which is transitioning out of the EU, say they have the power to authorize use of a Covid-19 vaccine in the U.K. before year-end, if they choose. The U.K. also has been reviewing Oxford and AstraZeneca's data on a rolling basis since early November. Canada has also begun a rolling review of the vaccine.

Monday's results are from trials held in the U.K. and Brazil. Late-stage clinical trials of the vaccine are continuing in the U.S. following a trial pause there that spanned most of September and October.

The results released Monday were based on trials involving more than 23,000 participants. Individuals who received the vaccine, called AZD1222, received one of two combinations: a half dose followed by a full dose, which showed to be 90% effective; or two full doses, which were 62% effective. Researchers said Monday the preliminary results were promising but will need to be fleshed out before scientists can understand why the half-dose regimen was more effective. They said more than 3,000 of the overall trial participants received the half-dose regimen.

Oxford's chief investigator in the trials, Prof. Andrew Pollard, said the results mean the vaccine "may be around 90% effective." The regimen using a half dose for the first dose would also mean more people could be vaccinated with planned supplies, he and AstraZeneca executives said.

Prof. Sarah Gilbert, one of Oxford's lead scientists on the vaccine, said researchers are digging into why the half-dose regimen has shown to be more effective. She said it could be that the lower first dose better mimics the natural human immune system, coaxing the body to be ready for an eventual fight against the virus in a way that makes the second, standard dose more effective.

Two-dose vaccines often behave differently from single-dose vaccines, Oxford scientists said. With the latter, a stronger dose is usually closely matched with higher efficacy. With two doses, the first dose acts as a prime for the second dose.

AstraZeneca will seek regulatory permission to alter its U.S. trials as quickly as possible based on these results in order to test more participants using the more-effective half-dose regimen, executives said Monday. More than 10,000 people in the U.S. have received the full-dose schedule, AstraZeneca said, adding that it hopes to add the half-dose schedule within a matter of weeks. The FDA must sign off on any new trial protocols and ultimately authorize the shot's use in the U.S.

The differing trial time lines mean that the vaccine could be available in the U.K., Europe and elsewhere before the U.S.

As trials continue, Oxford and AstraZeneca will continue to refine the efficacy readings, helping determine whether the more-positive results hold up across a broader population of participants. The Oxford-AstraZeneca vaccine trials ultimately will enroll as many as 60,000 participants globally. The U.K. drugmaker said that the full analysis of the results is being submitted for peer review.

A full review of broader global trial results and full safety data are still to come.

Some researchers also said that it will be important to compare the effectiveness and safety of the leading vaccine candidates side by side. Oxford and AstraZeneca officials said such comparisons are difficult at this stage, but added that different shots are likely to be effective in different people, which scientists expect to be a positive for fending off serious Covid-19 symptoms and halting the virus's spread.

Like with other Covid-19 vaccines in development, researchers don't yet know how long the positive effects of the shot last, which is key to understanding the required frequency of vaccination. It will also affect overall effectiveness in preventing the spread of the disease and helping jump-start stricken economies.

Oxford and AstraZeneca's vaccine uses a more traditional approach than the Moderna and Pfizer shots, which both rely on a new technology called messenger RNA to induce an immune response inside the body. AstraZeneca's vaccine instead relies on introducing a weakened, chimpanzee virus into the body to trigger the immune response.

"A particular strength of this vaccine is that it can be stored in a fridge," said Prof. Azra Ghani, chair in infectious disease epidemiology at Imperial College London. "This means that it can be distributed around the world using existing delivery mechanisms."

Oxford invented the vaccine along with a company spun out of the university called Vaccitech Ltd. In April, Vaccitech relinquished its rights to the vaccine to Oxford in exchange for a small slice of potential future royalties, enabling Oxford's exclusive deal with AstraZeneca.

In May, Oxford started Phase 2 and 3 human trials, and AstraZeneca in late August launched a large, final-stage U.S. study aiming to enroll 30,000 volunteers to test the vaccine. The study was paused in early September after a patient in a U.K. trial suffered from an unexplained illness. The FDA permitted the U.S. study to resume Oct. 23. The separate, final-stage trial in the U.K. also paused but was restarted within less than a week.

An independent safety committee determined the illness was either unrelated to the vaccine, or couldn't be linked to the vaccine because of a lack of information to determine a connection, according to an information sheet given to study volunteers and posted online by the University of Oxford.

Later, a participant in trials of the vaccine in Brazil died, but the country's health regulator immediately said the trials would continue. At the time, Oxford said it had carried out an assessment of the case in Brazil and that there were no concerns about the safety of the trial. An independent assessment of the case didn't present any concerns, AstraZeneca said.

Write to Jenny Strasburg at jenny.strasburg@wsj.com

(END) Dow Jones Newswires

11-23-20 0927ET

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 1.66% 7777 Delayed Quote.6.19%
BIONTECH SE 2.86% 108.44 Delayed Quote.33.02%
CHINESE PEOPLE HOLDINGS COMPANY LIMITED 0.00% 0.051 End-of-day quote.2.00%
EURO / BRAZILIAN REAL (EUR/BRL) 2.24% 6.6542 Delayed Quote.2.58%
MODERNA, INC. -1.47% 131.02 Delayed Quote.25.41%
PFIZER INC. 0.19% 36.55 Delayed Quote.-0.71%
US DOLLAR / RUSSIAN ROUBLE (USD/RUB) 0.07% 75.172 Delayed Quote.0.19%
All news about ASTRAZENECA PLC
03:26pTHE LATEST : Chicago opens restaurants, some bars with limits
01:09pUK vaccine roll-out speeds up but doctors want quicker second dose
12:49pAstraZeneca's Covid-19 Vaccine Shortfall Threatens EU Plans to Boost Inoculat..
11:41aPFIZER : UK doctors seek review of 12-week gap between vaccine doses
11:38aItaly PM says vaccine supply delays are serious contract violations
06:06aTHE LATEST : N.Y. seniors, churches to get vaccine prep kits
03:45aASTRAZENECA : UK doctors call for shorter gap between Pfizer vaccine doses
01/22Health Care Down Amid Vaccine-Rollout Concerns -- Health Care Roundup
01/22THE LATEST : Online vaccine appointments filling up in Kansas
01/22ALEXION INVESTOR ALERT BY THE FORMER : Kahn Swick & Foti, LLC Investigates Adequ..
More news
Financials (USD)
Sales 2020 26 404 M - -
Net income 2020 2 955 M - -
Net Debt 2020 13 238 M - -
P/E ratio 2020 42,5x
Yield 2020 2,65%
Capitalization 140 B 139 B -
EV / Sales 2020 5,79x
EV / Sales 2021 4,98x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Average target price 126,47 $
Last Close Price 106,39 $
Spread / Highest target 46,7%
Spread / Average Target 18,9%
Spread / Lowest Target -15,2%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
NOVARTIS AG2.73%220 726
MERCK & CO., INC.-1.00%204 882
PFIZER INC.-0.71%203 159